Still Bullish On HCV, Idenix Also Plans To Focus On Oncology, Other Infectious Diseases
This article was originally published in The Pink Sheet Daily
New Chief Scientific Officer Jacques Dumas says the clinical-stage firm intends to leverage its expertise in nucleoside discovery to create drug candidates for cancer and other infectious diseases. Concurrent with its drug development in hepatitis C, Idenix plans to address these other indications with the help of partners.
You may also be interested in...
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”